Fluicell attends Breakthrough T1D Clinical & Research Congress in Philadelphia
Fluicell attended the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia last week. Discussions centered on momentum in cell therapy for type 1 diabetes. Fluicell presented research on its islet engineering technology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluicell AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein. (C)
Fluicell attended the inaugural Breakthrough T1D Clinical & Research Congress in Philadelphia last week. Discussions centered on momentum in cell therapy for type 1 diabetes. Fluicell presented research on its islet engineering technology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence.
While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fluicell AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein. (C)